1Luzzio MJ,Besterman JM,Evans MG,et al.Novelwater soluble CPT analogs as inhibitors of Topo I[].Cancer Research.1993
2O’connor PM,Nieves NW,Kerrigan D,et al.S-phasepopulation analysis does not correlate with the cytotoxicity of CPT and 10, 11-methylenedioxy camptothecin inhuman colon carcinoma HT-29 cells[].Cancer Communications.1991
3Wall ME,Want MC,Cook CE,et al.Plant antitumoragents: I.The isolation and structure of camptothecin,a novel alkaloidal leukemia and tumor inhibitor fromCamptotheca acuminata[].Journal of the American Chemical Society.1966
5Hsing YH,Hertzberg R,Hecht S,et al.CPT inducesprotein-linked DNA breaks via mammalian DNA topoisomerase I[].Journal of Biological Chemistry.1985
6Kingsbury WD,Bochm JC,Jakas DR,et al.Synthesis of water-soluble(aminoalkyl)CPT analogues: Inhibition of topo I and antitumor activity[].Journal of Medicinal Chemistry.1991
7Want,MC,Ronman PE,Wall ME.Plant antitumoragents 18.Synthesis and biological activity of CPT analogues[].Journal of Medicinal Chemistry.1980
8Wall ME,Want MC,Nicholas AW,et al.Plant antitumor agents 30, synthesis and structure activity ofnovel CPT analogs[].Journal of Medicinal Chemistry.1993
9Giovanella BC,Stehlin JS,Wall ME,et al.DNA topoI-targeted chemotherapy of human colon cancer inxenografts[].Science.1989
10Takayama H,Watanade A,Hosokawa M,et al.Synthesis of a new class of CPT derivatives, the longchain fatty acid esters of 10-OH-CPT, as a potent prodrug candidates and their in vitro metabolic conversionby carboxylesterases[].Bioorganic and Medicinal Chemistry.1998
同被引文献19
1Van Ark-Otte J, Kedde MA, Van Der Vijgh WJF, et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells[J].Br J Cane, 1998, 77: 2171-2176.
2Guichard S, Terret C, Hennebelle L, et al. CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal eolon and liver tissues[J].BrJ Canc, 1999,80: 364-370.
3Danks MK, Morton CL, Krull EJ, et al. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy[J]. Clin Canc Res, 1999,5:917-924.
4Gupta E, Lestingi TM, Miek R, et al. Metabolic fate of irinotecan in humans: correlation of glueuronidation with diarrhea[J].Cane Res, 1994,54:3723-3725.
5Sparreboom A, de Jonge MJ, de Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients[J].Clin Canc Res, 1998,4:2747-2754.
6Iyer L, King CD. Genetic predisposition to the metabolism of irinotecan (CPT-11)[J]. J Clin Investig, 1998,101 : 847-854.
7Monaghan G, Ryan M, Seddon R, et al. Genetic variation in bilirubin UDP-glucuronosyltrans-ferase gene promoter and Gilbert' s syndrome[J]. Lancet, 1996, 347 : 578-581.
8Wasserman E, Myara A, Mick R, et al. Bilirubin (BIL) and SN-38: pharmacokinetic/pharmacodynamics correlation[J]. Ann Oncol, 1998,10:58.
9Santos A, Zannetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans[J].Clin Cane Res, 2000,6:2012-2020.
10Dodds HM, Haaz MC, Riou JF, et al. Identification of a new metabolite of CPT-11 (irinotecan) : pharmacological properties and activation to SN-38 [J]. J Pharmaeol Exp Ther, 1998,286: 578-583.
